Abstract
The World Health Organization and American Academy of Pediatrics both support continued breastfeeding beyond 12 months of age up to 24 months of age or beyond. Human milk oligosaccharides (HMOs) are the third most abundant solid component in breast milk. HMO concentrations in early breast milk have been well-characterized, but less is known about HMO profiles later in lactation. The goals of this literature review and meta-analysis of studies that analyzed HMO concentrations at 12 months of lactation or beyond were to identify the most abundant HMOs in breast milk at various timepoints throughout lactation and assess dynamic changes in HMO concentrations over time. Literature searches were conducted to identify studies on HMO quantification following PRISMA guidelines. Only studies that measured HMOs at/beyond one year of age were analyzed. In total, thirteen studies met eligibility criteria. The identity and number of HMOs measured in each study were recorded. HMOs that appeared in at least 10 articles, termed herein as core HMOs, were selected for further analysis. Concentrations of these HMOs, as well as total HMO levels, were grouped by timepoint (colostrum, 6-, 12-, and >12-months). Core HMOs were identified as 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′-sialyllactose (3′-SL), and 6′-sialyllactose (6′-SL). These HMOs accounted for >70% of the total HMO pool across timepoints. Total HMO concentrations decreased from colostrum to 6-months but plateaued at 12-months through 24 months. Individual core HMOs generally followed the same trend, with the exception of 3-FL, which increased in concentration over time through 12 months. Overall, HMO concentrations remained at significant levels through one year and the relative abundance of the core HMOs throughout lactation suggests biological relevance. Several studies have demonstrated associations between HMO concentrations in infants with outcomes in young children. Extending these analyses to include prolonged consumption of HMOs (> one year) would be of general interest to the field. To the best of our knowledge, this review is the first to specifically synthesize studies that analyzed HMO concentrations at 12 months lactation. Further research may enhance the understanding of the effects of HMOs beyond infancy and into young childhood.
1 Introduction
Breastfeeding is the gold standard of feeding for infants. The American Academy of Pediatrics (AAP) recently published their updated United States (US) policy statement that supports continued breastfeeding to two + years of age, as long as mutually desired by mother and child, with introduction of complementary foods at approximately six months of age (). This aligns with global breastfeeding recommendations by the World Health Organization (WHO) that emphasize breast milk is an important source of energy and nutrients in the second year of life, providing about one-third of energy needs, and may reduce mortality in malnourished children (). Despite these breastfeeding recommendations, only 35.9% of young children in the US are breastfed up to 12 months of age with no further data points reported (). Worldwide, approximately 70% of young children are breastfed up to 12 months of age, which decreases to 45% by 24 months of age ().
In breast milk, human milk oligosaccharides (HMOs) are the third most abundant solid component. HMO concentrations have been well-characterized from breast milk of mothers of infants (–). HMOs have been shown to have multi-functional benefits both preclinically () and clinically (), including in infants fed formula with added HMO (). Moreover, several studies from within the past decade have shown correlations between HMO consumption from breast milk in infancy and positive outcomes later in childhood (–). However, associations between extended consumption of HMOs beyond infancy and later outcomes have largely been unexplored to date. In general, young child nutrition is an understudied area (). Adding to this dearth of information, few studies have empirically investigated HMO concentrations beyond the first 3–6 months of lactation, and in those that have, measuring HMO concentrations at later timepoints has often not been the primary outcome. In fact, in a recent comprehensive review that compiled 57 studies in which HMO concentrations were measured throughout lactation, only two of the studies included measurements at 12 months of age (). Further, the authors of that review aggregated all data from measurements occurring beyond 90 days of lactation into one category, underscoring how later measurement timepoints may be obscured within heterogenous datasets.
In consideration of these points, we aimed to specifically compile studies in which HMO concentrations were analyzed at 12 months of age and beyond in order to assess dynamic changes in HMO concentrations at discrete timepoints later in lactation. To our knowledge, this review and meta-analysis is the first of its kind to summarize HMO concentrations in breast milk with a precise focus on timepoints beyond early infancy.
2 Materials and methods
Literature searches, concluding on January 31st, 2025, were conducted on PubMed and Google Scholar, with a combinations of search terms employed (human milk oligosaccharide(s) one year; human milk oligosaccharide(s) 12 months; human milk oligosaccharide(s) concentration; human milk oligosaccharide(s) quantification). Additionally, three previous literature reviews (–) assessing HMO concentrations were cross-referenced for additional articles. The main inclusion criterion was as follows: only studies that measured HMO concentrations in at least one instance at or beyond one year (or an approximation thereof) were considered for inclusion. Where applicable, earlier measurement timepoints from these specific studies were used as reference points in the downstream data analysis. Additionally, only peer-reviewed articles published in or translated to English which had available datasets that could be reasonably obtained were included. Exclusion was performed independently by two authors (ADK and ASD). The full PRISMA workflow used for article exclusion can be found in Figure 1. In total, 13 research articles met all inclusion criteria (–). Key characteristics of these studies are represented in Table 1.
Figure 1
Table 1
| Ref. | Sample size | Country | Secretor status definition | Measurement timepoints (postpartum) | HMOs measured | No. of HMOs measured | Analysis method |
|---|---|---|---|---|---|---|---|
| () | 435 mothers | Chile, China, France, Italy, Mexico, USA, Philippines, Singapore, Sweden | Not Determined | 0–2, 3–10, 11–30, 31–452 days | 2′-FL, 3-FL, DFL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, LNFP-V | 9 | High-performance anion-exchange chromatography (HPAEC) |
| () | 131 longitudinal breast milk samples from 19 mothers and 33 unpasteurized, pooled human milk samples from Mother's Milk Bank | USA | Not Determined | 9–17 months | Total of: 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNFP-I, LNFP-II, LNFP-III, LDFT, LNDFH-I, LNDFH-II, DSLNT, SLNFP-II, MNT, SLNFP-IV, MNnT | Total of 16 HMOs | Carbon high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS) |
| () | 26 mothers | Malaysia | Not Determined | Colostrum (<5 days), 60, 180, 365 days | 2′-FL, 3-FL, 3′-SL, 6′-SL, DSL, LNT, LNnT, 6′-SLN, 3′-S3FL, LSTa/b, LSTc, Total LNFP | 12 | Hydrophilic interaction liquid chromatography with mass spectrometry (HILIC-MS) |
| () | n = 156 (3 months) n = 122 (6 months) n = 28 (12 months) | Germany | FUT2 SNP rs601338 | 3, 6, 12 months | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LDFT, LNDFH-I, 3′-GL, 6′-GL, LSTb, LSTc, LNnDFH, LNnFP-V, A-tetra, DSLNT, DFLNHa, LNH, MFLNH-III Hex4 HexNAc2 | 24 | Liquid chromatography with mass spectrometry (LC-MS) |
| () | n = 207 (1 month) n = 109 (6 months) n = 83 (12 months) n = 59 (18 months) n = 28 (24 months) | USA | Presence or near absence of 2′-FL (<100 nmol/ml) | 1, 6, 12, 18, 24 months | 2′-FL, 3-FL, DFL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, LNH, DFLNHa, DFLNT, DSLNH, DSLNT, LSTb, LSTc, FDSLNH, FLNH | 19 | HPLC |
| () | n = 682 (6 weeks) n = 448 (6 months) n = 73 (12 months) | Germany | Defined but HMO levels were not stratified by group | 6 weeks, 6 months, 12 months | 2′-FL, 3-FL, DFL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNnDFH II, 6′-GL | 15 | Targeted liquid chromatography electrospray ionization with tandem mass spectrometry (LC-ESI-MS) |
| () | 488 samples from 335 mothers | China | Not Determined | 0–5, 10–15, 40–45, 200–240, 300–400 days | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT | 6 | High-performance anion-exchange chromatography- pulsed ampero-metric detector (HPAEC-PAD) |
| () | 167 samples from 71 mothers | United Kingdom | FUT2 SNP rs516246 G/G and A/G alleles = secretor A/A allele = non-secretor | Birth, 2 weeks, 6 weeks, 3 months, 6 months, 12 months | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I | 7 | HPAEC |
| () | 383 samples from 277 mothers n = 100 (0–5 days) n = 20 (10–15 days) n = 91 (40–45 days) n = 93 (200–240 days) n = 79 (300–400 days) | China | Presence of 2′-FL >200 mg/L | 0–5, 10–15, 40–45, 200–240, 300–400 days | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT | 6 | HPAEC-PAD |
| () | 481 milk samples (random sub- sample from larger study) | China | Levels of 2′-FL, LDFT, LNFP-I, and LNnDFH-I | Colostrum (0–6 days), Transitional milk (7–14 days), Mature milk (15–340 days) | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, DSLNT, LDFT, LSTb, LSTc, [LNDFH-I + LNnDFH-I], LNDFH-II, LNnDFH-II, MFLNH-I, MFLNH-III, MFLNnH, DFLNHa, DFpLNnH, [3′-SLNFPII + 6′-SLNFPVI] | 22 | Ultra-high performance liquid chromatography with mass spectrometry and multi-reaction monitoring (UPLC-MRM) |
| () | 1,758 mothers | China | Low and high 2′-FL noted | 0–5, 10–15, 40–45, 200–240, 300–400 days | 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT | 6 | HPAEC-PAD |
| () | Longitudinal breast milk samples from 210 mothers n = 210 (1 month) n = 131 (6 months) n = 84 (12 months) | USA | Not Determined | 1, 6, 12 months | 2′-FL, 3-FL, 3′-SL, 6′-SL, DFL, LNT, LNnT, LNFP-I, LNFP-II, LNFP-III, DFLNT, DSLNT, LNH, FLNH, DFLNH, FDSLNH, DSLNH, LSTb, LSTc | 19 | HPLC |
| () | 129 mothers n = 36 (0–3 months) n = 33 (3–6 months) n = 43 (6–9 months) n = 15 (9–12 months) | China | Not Determined | 0–3, 3–6, 6–9, 9–12 months | 2′-FL, 3-FL, 3′-SL, 6′-SL | 4 | Nuclear magnetic resonance (NMR) |
Overview of articles included in the literature review. Articles are listed chronologically.
Identities of the individual HMOs and total number of HMOs measured in each study were recorded. For each unique HMO, the measurement frequency was calculated from a total possible inclusion score of 13 (Figure 2). HMOs that appeared in a minimum of ten articles, termed herein as core HMOs, were selected for further analy-sis and were as follows: 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL), lacto-N-tetraose (LNT), and lac-to-N-neotetraose (LNnT). Concentrations of these six core HMOs were extracted from the available datasets and supplemental materials and compiled by selected timepoints of interest (colostrum and 6 months of age as reference timepoints, 12 months of age, and all timepoints >12 months up to 24 months of age).
Figure 2
Additional curation of the data prior to analysis included standardizing all data-points to be presented as g/L and calculating total HMO levels at each timepoint (when not explicitly provided in the individual studies) by summing the mean values of all HMOs measured in that study. In the case of Mokhtari et al., conversion from nmol/ml to g/L could not reliably be performed for all HMOs measured, since molecular mass data could not be obtained for DFLNT and FDSLNH. As such, individual HMO concentrations were assessed for the core HMOs, but total concentrations were not calculated from this study (). Further, necessary binning of timepoints that were not explicitly defined based on the above definitions was performed. For example, samples that were not defined explicitly as colostrum but that were measured on or before five days lactation were also considered to be colostrum samples. In some instances, the closest approximation to the defined timepoints was used, such as HMO concentrations measured at 180 days being included in the 6 months of age group, or values from a timepoint of “300–400 days” being included in the 12 months of age group. In general, reasonable timepoint approximations were used wherever possible to avoid further narrowing of the dataset. Finally, data striated based on secretor status were treated as separate datapoints, where applicable. Concentrations of 2′-FL from non-secretor samples were excluded from the analysis, as these values were near zero, consistent with findings that 2′-FL is largely undetectable in milk from non-secretors (, ).
The compiled values for the six core HMOs, as well as total HMO concentrations, across these 13 studies were then graphed, with bars representing the overall mean-of-means and error bars representing standard deviation (Figure 3, Table 2). From this analysis, relative proportions of these HMOs in comparison to total HMO levels at each timepoint were calculated by taking the quotient of individual HMO averages divided by the total HMO average and multiplying by 100%, with “other” being calculated as 100% - [Sum % of 2′-FL, 3-FL, 3′-SL, 6′-SL, LNT, LNnT] (Figure 4, Table 2).
Figure 3
Table 2
| HMO | Timepoint | |||||
|---|---|---|---|---|---|---|
| Colostrum | 6mo | 12mo | ||||
| Concentration (g/L) | Relative abundance (%) | Concentration (g/L) | Relative abundance (%) | Concentration (g/L) | Relative abundance (%) | |
| 2′-FL | 3.00 | 38.9 | 1.82 | 35.5 | 1.59 | 29.7 |
| 3-FL | 0.38 | 4.9 | 1.23 | 24.1 | 1.45 | 27.1 |
| LNT | 1.31 | 16.9 | 0.50 | 9.8 | 0.50 | 9.5 |
| LNnT | 0.55 | 7.1 | 0.13 | 2.6 | 0.12 | 2.3 |
| 3′-SL | 0.21 | 2.7 | 0.20 | 3.8 | 0.24 | 4.4 |
| 6′-SL | 0.52 | 6.8 | 0.08 | 1.6 | 0.06 | 1.1 |
| Total | 7.72 | — | 5.12 | — | 5.34 | — |
Concentration and relative abundance of the six core HMOs at 0–12 months of age across the 13 studies analyzed.
Italicized values represent relative abundance (%) of the specified individual HMO in comparison to total HMO concentration at each timepoint. These values are represented graphically in Figure 4.
Figure 4
3 Results
In total, 42 unique HMOs were measured at least once across the 13 articles, with over a third of these HMOs (38.1% or 16 of 42 HMOs) only appearing in one instance across all studies. Only ten HMOs were represented in at least half of the included studies. The six core HMOs selected for further analysis, defined above as those that were analyzed in at least ten studies, included 2′FL, 3-FL, 3′-SL, 6′-SL, LNT, and LNnT. One study () reported total HMO levels based on 16 HMOs, including 2′-FL, 3-FL, 3′-SL, 6′-SL and LNT. Only 2′-FL and 3-FL were measured in every study. The identity of HMOs measured and the number of articles in which they appear are summarized in Figure 2.
The most common timepoints where HMOs were measured in these studies were in colostrum and at 6- and 12-months of age. Most studies concluded measurements at one year. Only Perrin et al. () (monthly measurements of total HMO levels up to 17 months of age) and Plows et al. () (individual concentrations of 19 HMOs at 18- and 24-months of age) measured HMOs at appreciably later timepoints. As such, our analysis of individual HMO levels was capped at 12 months of age, with colostrum and 6-month timepoints serving as reference points from which changes in HMO concentrations could be assessed. We included an additional timepoint (>12 months of age) for total HMO concentrations which represents aggregated data from n = 9 datapoints, comprising all measurements from 13 to 24 months of age in two studies (, ).
Our analysis revealed that 2′-FL was the most abundant HMO in breastmilk across all timepoints (Figure 3A, Table 2). At an average concentration of 3.00 g/L in colostrum, this was more than double the level of the next most abundant HMO, which was LNT at 1.31 g/L (Figures 3A,E, Table 2). Moreover, despite a significant decline in concentration over the course of lactation, 2′-FL remained slightly more abundant at 12 months compared to 3-FL (1.59 g/L vs. 1.45 g/L) (Figures 3A,B, Table 2). These data align with previous observations that 2′-FL is the most prominent breastmilk oligosaccharide (). Inversely, 3-FL, the second most abundant fucosylated oligosaccharide in breastmilk, was the only HMO found to significantly increase over time (0.38 g/L in colostrum vs. 1.45 g/L at 12 months, a nearly four-fold increase) (Figure 3B, Table 2). The remaining HMOs that were analyzed either decreased from colostrum to 12 months of age (6′-SL, LNT, and LNnT) or plateaued (3′-SL) (Figures 3C–F, Table 2). Total HMO concentrations also declined throughout lactation (7.72 g/L in colostrum to 5.34 g/L at 12 months) (Figure 3G, Table 2). HMO concentrations from all timepoints >12 months of age ranged from 7.2 g/L to 10.1 g/L, with an average concentration of 8.47 g/L (Figure 3H). These data are plotted separately given that all datapoints originated from only two studies, making statistical comparisons to previous timepoints not possible. Proportionally, the six core HMOs accounted for more than 70% of the total HMO pool at each timepoint (Figures 4A–C, Table 2).
4 Discussion
Whereas the breadth of literature investigating breast milk HMO levels during the infancy year is extensive and diverse, the number of studies analyzing at or beyond 12 months of age is comparatively limited. As previously mentioned, Soyyilmaz et al. recently published an extensive review covering HMO levels throughout lactation, amounting to 57 publications (). In contrast, the dataset included herein is derived from a pool of literature <25% of that scale despite less stringent inclusion criteria, underscoring that the focus in the field has been predominantly early lactation. However, the cumulative sample size (n = 4,786) across all studies included was still quite robust. Moreover, the authors of that study aggregated all data from measurements occurring be-yond 90 days of lactation into one category (). Nonetheless, the findings reported here are largely in agreement with what has been previously published on HMO levels in early milk. Specifically, the relative abundance of selected HMOs and trends in total HMO levels (overall decline) over time were consistent out to 12 months of age (Figure 3). Of note, there was some minor variation between the relative abundance of the core HMOs reported here and what has been described previously. This can likely be attributed to the aforementioned smaller sample size of studies included in this review, which precluded further analysis of additional predominant HMOs, such as LNFP-I and LNDFH-I. Interestingly, the aggregated values for total HMO levels from all >12 months of age timepoints represented the highest average concentration of any timepoint. However, because these datapoints were compiled from a wide range of collection timepoints across a much smaller pool of studies, any meaningful comparison should be drawn with caution until more substantive analysis can be completed from a larger pool of data which may become available from future studies.
There are several other key considerations that may further shape interpretation of the data presented herein. In an analysis comprising so few studies and in which there exists disparity in analysis methods, experimental design, and data reporting, intra-study variation will inherently lend greater influence on the overall results. Specific factors that could not be controlled for here, due to the necessarily lenient exclusion criteria, include HMO analytical method, definition and striation of secretor vs. non-secretor milk, geographic location of the studies, relative sample size consistency across timepoints, health of the mother/infant dyads, and birth/delivery mode of the infant. For instance, the studies that utilized HPLC tended to quantify a more diverse set of HMOs (12–24 HMOs) compared to those that used HPAEC (6–9 HMOs), both of which were greater than the one study that employed NMR analysis (4 HMOs) (Table 1). Even within conserved methods across studies, there was considerable variation in the data reported. Moreover, since the studies represented herein analyzed a variety of HMOs, it stands to reason that the most commonly measured core HMOs may have been overrepresented in studies where these HMOs comprised most, or all, of the total HMO pool measured in that particular study (Figure 4). This may also be an example of confirmation bias, wherein these HMOs have historically been considered among the most abundant HMOs in breastmilk (, , ) and therefore emphasis was placed on including them in the analysis (Figure 2). Additionally, secretor status of the mother is well-established to disproportionately affect levels of certain HMOs, namely 2′-FL (, , ), yet secretor status was only considered for data presentation in five studies, with variable definitions for determining secretor vs. non-secretor in each (Table 1). Likewise, impact of geographical origin of the samples on HMO concentrations was not considered here despite disparate sampling across the United States, Asia, and Europe, although previous reports have suggested that there are significant differences in HMO levels across the globe (). Where sample size was reported by individual timepoint in contrast to overall sample size, late timepoint n numbers were consistently the lowest values and in some cases were nearly 10-fold lower compared to early timepoints (Table 1), which may have introduced further variability within certain portions of the datasets. Indeed, even from six to 12 months of age, cumulative sample size from this subset of studies decreased from n = 936 at six months of age to n = 362 at 12 months of age, representing a 61% reduction in the number of mothers represented. Other factors, such as health of the mother/infant dyads and birth/delivery mode, were often not reported within the studies at all, although the contribution of these factors to breastmilk HMO concentrations is unclear. Taken together, these considerations underscore the inherent difficulty in drawing overarching conclusions about HMO levels at later timepoints in lactation and highlight a key knowledge gap in the field which warrants further study. Nonetheless, the results herein highlight the significant contributions of the so-called core HMOs to the overall HMO pool throughout lactation and suggest that total HMO levels remain at biologically significant levels through the first two years of breastfeeding.
Interestingly, only one study included in this review was published prior to the last decade. The remaining studies were published between 2017-present, potentially indicating a shift in interest/focus to HMO levels beyond one year, in alignment with updated US breastfeeding guidelines that support breastfeeding beyond one year (, ). Despite this recent attention, more research focused specifically on HMO concentrations beyond one year of lactation is warranted. Intriguingly, an increasing number of breast milk association studies have been published relating HMO concentrations in breast milk during infancy to positive outcomes into young childhood (–). Extending these analyses to include prolonged consumption of HMOs up to two years would be valuable to the field. Additionally, if a young child is not receiving breast milk, HMOs may be provided by select young child formulas/toddler drinks and/or dietary supplements intended for young children, when warranted.
Statements
Author contributions
AK: Formal analysis, Visualization, Conceptualization, Writing – original draft, Writing – review & editing, Data curation. AS-D: Writing – original draft, Conceptualization, Writing – review & editing. M-MS: Writing – original draft, Writing – review & editing. RB: Writing – review & editing, Writing – original draft. ER: Writing – original draft, Conceptualization, Supervision, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
Authors AK, AS-D, M-MS, RB and ER were employed by and are stakeholder of Abbott Nutrition.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
MeekJYNobleL, Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk. Pediatrics. (2022) 150:e2022057988. 10.1542/peds.2022-057988
2.
WHO. Infant and young child feeding. (2023).
3.
CDC. Breastfeeding Report Card. (2024).
4.
UNICEF/WHO. GLOBAL BREASTFEEDING SCORECARD 2023. (2023).
5.
ThurlSMunzertMBoehmGMatthewsCStahlB. Systematic review of the concentrations of oligosaccharides in human milk. Nutr Rev. (2017) 75:920–33. 10.1093/nutrit/nux044
6.
ThumCWallCRWeissGAWangWSzetoIMYDayL. Changes in HMO concentrations throughout lactation: influencing factors, health effects and opportunities. Nutrients. (2021) 13:2272. 10.3390/nu13072272
7.
SoyyılmazBMikšMHRöhrigCHMatwiejukMMeszaros-MatwiejukAVigsnæsLK. The mean of milk: a review of human milk oligosaccharide concentrations throughout lactation. Nutrients. (2021) 13:2737. 10.3390/nu13082737
8.
UrashimaTAjisakaKUjiharaTNakazakiE. Recent advances in the science of human milk oligosaccharides. BBA Adv. (2025) 7:100136. 10.1016/j.bbadva.2024.100136
9.
HillDRChowJMBuckRH. Multifunctional benefits of prevalent HMOs: implications for infant health. Nutrients. (2021) 13:3364. 10.3390/nu13103364
10.
BodeL. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. (2012) 22:1147–62. 10.1093/glycob/cws074
11.
SchonknechtYBMoreno TovarMVJensenSRParschatK. Clinical studies on the supplementation of manufactured human milk oligosaccharides: a systematic review. Nutrients. (2023) 15:3622. 10.3390/nu15163622
12.
BergerPKBansalRSawardekarSYonemitsuCFurstAHampsonHEet alAssociations of human milk oligosaccharides with infant brain tissue organization and regional blood flow at 1 month of age. Nutrients. (2022) 14:3820. 10.3390/nu14183820
13.
BergerPKOngMLBodeLBelfortMB. Human Milk Oligosaccharides and Infant Neurodevelopment: A Narrative Review. Nutrients. (2023) 15:719. 10.3390/nu15030719
14.
BergerPKPlowsJFJonesRBAldereteTLYonemitsuCPoulsenMet alHuman milk oligosaccharide 2'-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers. PLoS One. (2020) 15:e0228323. 10.1371/journal.pone.0228323
15.
OliverosEMartínMJTorres-EspínolaFJSegura-MorenoMTRamírezMSantosAet alHuman milk levels of 2-fucosyllactose and 6-sialyllactose are positively associated with infant neurodevelopment and are not impacted by maternal BMI or diabetic status. J Nutr Food Sci. (2021) 4:100024.
16.
SatoKNakamuraYFujiyamaKOhnedaKNobukuniTOgishimaSet alAbsolute quantification of eight human milk oligosaccharides in breast milk to evaluate their concentration profiles and associations with infants’ neurodevelopmental outcomes. J Food Sci. (2024) 89:10152–70. 10.1111/1750-3841.17597
17.
ChoSZhuZLiTBaluyotKHowellBRHazlettHCet alHuman milk 3'-sialyllactose is positively associated with language development during infancy. Am J Clin Nutr. (2021) 114:588–97. 10.1093/ajcn/nqab103
18.
MansellTFurstAO'HelyMChangMPonsonbyA-LVuillerminPet alAge-dependent associations of human milk oligosaccharides with body size and composition up to 4 years of age. Am J Clin Nutr. (2023) 117:930–45. 10.1016/j.ajcnut.2023.02.016
19.
WejrydEFreiholtz JernEMarchiniGÅdenULandbergEAbrahamssonT. Human milk oligosaccharides in breast milk at two weeks of age in relation to neurodevelopment in 2-year-old children born extremely preterm. An Explorative Trial. Nutrients. (2025) 17:832. 10.3390/nu17050832
20.
SawaneKTakahashiIIshikuroMTakumiHOruiMNodaAet alAssociation between human milk oligosaccharides and early adiposity rebound in children: a case-control study of the tohoku medical megabank project birth and three-generation cohort study. J Nutr. (2025) 155:1498–507. 10.1016/j.tjnut.2025.02.024
21.
ReverriEJArensbergMBMurrayRDKerrKWWulfKL. Young child nutrition: knowledge and surveillance gaps across the Spectrum of feeding. Nutrients. (2022) 14:3093. 10.3390/nu14153093
22.
ErneyRMMaloneWTSkeldingMBMarconAAKleman-LeyerKMO'RyanMLet alVariability of human milk neutral oligosaccharides in a diverse population. J Pediatr Gastroenterol Nutr. (2000) 30:181–92. 10.1097/00005176-200002000-00016
23.
PerrinMTFoglemanADNewburgDSAllenJC. A longitudinal study of human milk composition in the second year postpartum: implications for human milk banking. Matern Child Nutr. (2017) 13:e12239. 10.1111/mcn.12239
24.
MaLMcJarrowPMohamedHJBLiuXWelmanAFongBY. Lactational changes in the human milk oligosaccharide concentration in Chinese and Malaysian mothers’ milk. Int Dairy J. (2018) 87:1–10. 10.1016/j.idairyj.2018.07.015
25.
LefebvreGShevlyakovaMCharpagneAMarquisJVogelMKirstenTet alTime of lactation and maternal fucosyltransferase genetic polymorphisms determine the variability in human milk oligosaccharides. Front Nutr. (2020) 7:574459. 10.3389/fnut.2020.574459
26.
PlowsJFBergerPKJonesRBAldereteTLYonemitsuCNajeraJAet alLongitudinal changes in human milk oligosaccharides (HMOs) over the course of 24 months of lactation. J Nutr. (2021) 151:876–82. 10.1093/jn/nxaa427
27.
SizibaLPMankMStahlBGonsalvesJBlijenbergBRothenbacherDet alHuman milk oligosaccharide profiles over 12 months of lactation: the ulm SPATZ health study. Nutrients. (2021) 13:1973. 10.3390/nu13061973
28.
LiuSCaiXWangJMaoYZouYTianFet alSix Oligosaccharides’ variation in breast milk: a study in south China from 0 to 400 days postpartum. Nutrients. (2021) 13:4017. 10.3390/nu13114017
29.
DurhamSDRobinsonRCOlgaLOngKKChichlowskiMDungerDBet alA one-year study of human milk oligosaccharide profiles in the milk of healthy UK mothers and their relationship to maternal FUT2 genotype. Glycobiology. (2021) 31:1254–67. 10.1093/glycob/cwab057
30.
LiXMaoYLiuSWangJLiXZhaoYet alVitamins, vegetables and metal elements are positively associated with breast milk oligosaccharide composition among mothers in Tianjin, China. Nutrients. (2022) 14:4131. 10.3390/nu14194131
31.
RenXYanJBiYShuttleworthPWWangYJiangSet alHuman milk oligosaccharides are associated with lactation stage and lewis phenotype in a Chinese population. Nutrients. (2023) 15:1408. 10.3390/nu15061408
32.
LiuSMaoYWangJTianFHillDRXiongXet alLactational and geographical variation in the concentration of six oligosaccharides in Chinese breast milk: a multicenter study over 13 months postpartum. Front Nutr. (2023) 10:1267287. 10.3389/fnut.2023.1267287
33.
MokhtariPSchmidtKAZamanianHBabaeiMMachleCJTrifonovaDet alMaternal diet associated with oligosaccharide abundances in human milk from Latina mothers. Nutrients. (2024) 16:1795. 10.3390/nu16121795
34.
ChenGChenLWangHZhangJSunXChenXet al(1)H nuclear magnetic resonance-based metabolomic profiling and comparison of human milk across different lactation stages in secretors and nonsecretors: a study of Chinese lactating women. J Nutr. (2025) 155:78–86. 10.1016/j.tjnut.2024.10.050
35.
PageMJMcKenzieJEBossuytPMBoutronIHoffmannTCMulrowCDet alThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. 10.1136/bmj.n71
36.
PageMJMoherDBossuytPMBoutronIHoffmannTCMulrowCDet alPRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. (2021) 372:n160. 10.1136/bmj.n160
37.
GrollmanEFGinsburgV. Correlation between secretor status and the occurrence of 2'-fucosyllactose in human milk. Biochem Biophys Res Commun. (1967) 28:50–3. 10.1016/0006-291X(67)90404-4
38.
KellyRJRouquierSGiorgiDLennonGGLoweJB. Sequence and expression of a candidate for the human secretor blood group alpha(1,2)fucosyltransferase gene (FUT2). homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem. (1995) 270:4640–9. 10.1074/jbc.270.9.4640
39.
HegarBWibowoYBasrowiRWRanuhRGSudarmoSMMunasirZet alThe role of two human milk Oligosaccharides, 2'-Fucosyllactose and Lacto-N-Neotetraose, in infant nutrition. Pediatr Gastroenterol Hepatol Nutr. (2019) 22:330–40. 10.5223/pghn.2019.22.4.330
40.
KobataA. Structures and application of oligosaccharides in human milk. Proc Jpn Acad Ser B Phys Biol Sci. (2010) 86:731–47. 10.2183/pjab.86.731
41.
KunzCMeyerCColladoMCGeigerLGarcía-MantranaIBertua-RíosBet alInfluence of gestational age, secretor, and lewis blood group status on the oligosaccharide content of human milk. J Pediatr Gastroenterol Nutr. (2017) 64:789–98. 10.1097/MPG.0000000000001402
42.
McGuireMKMeehanCLMcGuireMAWilliamsJEFosterJSellenDWet alWhat’s normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. Am J Clin Nutr. (2017) 105:1086–100. 10.3945/ajcn.116.139980
Summary
Keywords
human milk oligosaccharides, HMO, concentrations, review, meta-analysis
Citation
Kenney AD, Sabag-Daigle A, Stoecklein M-M, Buck RH and Reverri EJ (2025) A review of human milk oligosaccharide concentrations of breast milk for infants and young children through 24 months of age. Front. Pediatr. 13:1649609. doi: 10.3389/fped.2025.1649609
Received
18 June 2025
Accepted
18 August 2025
Published
04 September 2025
Volume
13 - 2025
Edited by
Matthew Wyatt Carroll, University of Alberta, Canada
Reviewed by
Sylwia Jarzynka, Medical University of Warsaw, Poland
Tadasu Urashima, Obihiro University of Agriculture and Veterinary Medicine, Japan
Updates
Copyright
© 2025 Kenney, Sabag-Daigle, Stoecklein, Buck and Reverri.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adam D. Kenney adam.kenney@abbott.com Elizabeth J. Reverri elizabeth.reverri@abbott.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.